DANAHER CORP /DE/ (DHR)
SEC filings, financial facts, source resources, and Goglides workspace context for DANAHER CORP /DE/.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
6Results2Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
DVLT Vivasor Filing: Ownership Signal or Selling Pressure?
A filing-backed DVLT update explaining Vivasor's Form 3 initial position, Form 4 20M-share sale, Schedule 13G remaining stake, and the proof gate investors should monitor.
OpenDVLT's $2B term sheet: financing breakthrough or dilution trap?
Datavault AI's $2.0B structured financing term sheet could give the company a collateral base and global tokenization mandate, but the deal is non-binding, potentially dilutive, and loaded with proof gates.
OpenDVLT $2B structured financing explained for beginners
A beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
OpenDanaher Vs Agilent: Which Life Science Giant Wins The Recurring Revenue War?
Danaher and Agilent both sell into durable lab workflows, but the winner depends on recurring mix, margin quality, and cash conversion.
OpenDanaher: life-science quality has to show up in bioprocess recovery and cash conversion
Danaher reported 2025 revenue of $24.57 billion and Q1 2026 revenue of $5.95 billion. The thesis depends on bioprocess recovery, diagnostics demand, operating leverage, acquisitions and cash conversion.
Open